Abbott spent the better part of a decade becoming something harder to categorize than a drug company. It makes the glucose sensor on a diabetic teenager’s arm, the catheter threading through a heart in an electrophysiology lab, the cancer screening test a gastroenterologist orders, and the infant formula on a grocery shelf. That breadth was the strategy: no single product cliff, no single payer fight. Then, in the first quarter of 2026, Abbott swallowed Exact Sciences whole, adding a colonoscopy-alternative business that nearly doubled its cancer diagnostics footprint overnight. The stock, meanwhile, sits well below its 52-week high. The math and the mood are telling different stories.
What matters here
The filed numbers show a business where medical devices and pharmaceuticals are accelerating while nutrition is actively shrinking, and where a major acquisition is simultaneously adding revenue and diluting near-term earnings. The stock’s price-to-earnings multiple sits above Abbott’s own decade median, even as the share price has fallen over the past year. A business growing faster in its largest segment is priced above its historical average, yet trading well off its highs. Those two readings don’t resolve easily, and that gap is the story.
The quarter that just closed
The 10-Q for the quarter ended June 30, 2026 shows total sales of $12.6 billion, up about 13% from the same quarter a year earlier, with comparable sales growth (which strips out currency swings and the Exact Sciences addition) running near 5%. The headline is tidy. What’s underneath is less so.
Medical Devices, now the company’s largest segment, posted $5.9 billion in Q2 sales with comparable growth of 8.4%. The engine inside that number is continuous glucose monitoring: CGM sales crossed $2 billion in the quarter alone, growing nearly 10%. Abbott has been building toward this for years. The FDA cleared FreeStyle Libre sensors for automated insulin delivery systems in early 2023, then the company launched over-the-counter monitors in mid-2024, and the Volt pulsed field ablation catheter received FDA approval late in 2025. Each of those approvals opened a new lane. The devices segment is now running at a pace that would represent roughly half of Abbott’s total revenue on an annualized basis.
Nutrition is the other side of the ledger. Sales fell on a comparable basis in Q2, and that’s not a rounding error, it’s a segment actively losing ground. Management attributed it to pricing decisions made in late 2025 and lower volumes. A meaningful sequential improvement from Q1 to Q2 suggests the slide may be stabilizing, but the segment has not yet returned to growth.
The acquisition that changes the shape of things
On March 23, 2026, Abbott completed its purchase of Exact Sciences, the maker of Cologuard, a stool-based colorectal cancer screening test. The deal is expected to add roughly $3 billion in cancer diagnostics revenue for 2026, which is roughly half of what Abbott’s Established Pharmaceuticals segment earns in a year on an annualized basis. Cancer diagnostics within the broader Diagnostics segment saw mid-teens growth in Q2, directly reflecting the addition.
The cost of that growth is visible in the earnings line. The acquisition initially diluted full-year adjusted EPS guidance by a meaningful amount, meaning Abbott paid for future revenue with present-day profit. The 10-K for fiscal year 2025 disclosed substantial restructuring charges and after-tax charges excluded from adjusted earnings, covering amortization, impairments, and acquisition costs. Adjusted figures, the ones management emphasizes, look cleaner than the filed totals. The gap between the two is worth holding in mind.
What the margin line is actually saying
Gross margin, the share of each sales dollar left after making the product, came in at 52.5% for Q2 2026, fractionally below the rate recorded in Q2 2025. That’s a small move, but it runs against the full-year 2025 trend: the annual filing showed gross margin improving to 56.4% for the full year, up a full percentage point from 2024. The quarterly dip likely reflects the Exact Sciences integration, which brings a different cost structure into the mix. Whether the full-year margin holds at the 2025 level or drifts toward the Q2 reading is a question the next two quarters will answer.
R&D spending for 2025 reached roughly 7% of that year’s revenue, a modest increase from 2024. For a company whose growth story depends on device approvals and diagnostic launches, that number is the seed corn. Cutting it would be a warning sign; holding it steady while revenue grows is the minimum acceptable outcome.
The balance sheet, simplified
Long-term debt stood at $9.9 billion at the end of 2025, down sharply from where it stood in 2021. Think of it this way: Abbott has paid off roughly 43% of its debt pile in four years, long-term debt fell from $17.3 billion in 2021 to $9.9 billion at end of 2025, which is a meaningful shift in financial flexibility. Free cash flow for 2025 was $7.4 billion, meaning the company generated enough cash to cover its entire remaining debt load in less than a year and a half. In Q2 2026 alone, Abbott returned $2.1 billion to shareholders through dividends and buybacks. The Exact Sciences acquisition will have added to the debt load, though the Q2 filing does not yet show the full post-close balance sheet in the available summaries.
What the outside conversation is saying
On August 13, 2026, Wolfe Research upgraded Abbott to Outperform, citing a valuation level of $130 as consistent with its outlook, the Q2 beat, and potential for cost synergies from Exact Sciences that management may have under-guided. Six days later, Seeking Alpha’s Gen Alpha moved the other direction, downgrading on valuation grounds. Both reactions are coherent given the same set of facts: the business is performing well, and the stock is not cheap by its own history.
Our data puts the current price-to-earnings multiple at 30 times, against Abbott’s own decade median of 27.7 times. On price-to-sales, the picture reverses: the current reading sits below the decade median, at the lower third of Abbott’s own history. The math says the revenue is relatively modestly priced; the earnings multiple says the opposite. That split reflects the gap between reported and adjusted earnings, and the market’s uncertainty about which number to trust as the integration settles.
Reading the numbers
$12.6 billion in Q2 2026 sales. This is what Abbott billed in a single quarter across all four segments. To feel the scale: it’s roughly what a mid-size country spends on healthcare in a year. What it means here is that Abbott is now running at an annualized revenue pace well above its full-year 2025 total of $44.3 billion, partly because Exact Sciences wasn’t in the 2025 base. The comparison will look flattering for the rest of 2026 and then normalize.
8.4% comparable devices growth. Comparable growth strips out acquisitions and currency, so this is the organic engine. A household analogy: if a family’s income grew 8.4% in a year while prices rose roughly 3%, that’s a real gain of about 5%, which is meaningful. For Abbott, this rate, sustained across a segment that is nearly half the company, is the core of the bull case.
3.6% comparable nutrition decline. For every $100 of infant formula and adult nutrition products Abbott sold in Q2 2025, it sold about $96 in Q2 2026. That’s not catastrophic, but it’s a drag on a business where every other segment is growing. The sequential improvement from Q1 suggests the floor may be near, but the filed numbers don’t yet confirm a turn.
52.5% gross margin in Q2 2026 vs. 56.4% for full-year 2025. The quarterly figure is lower because it includes the newly acquired Exact Sciences business, which carries different economics. If the full-year 2026 margin settles closer to the quarterly rate than the annual 2025 rate, that’s a meaningful change in how much profit each dollar of revenue produces. The data cannot yet answer which way this resolves.
$7.4 billion free cash flow for 2025. Free cash flow is what’s left after the company pays to keep itself running and invest in new equipment, the money available for debt paydown, dividends, and buybacks. At $7.4 billion, Abbott generated more cash in 2025 than the entire market value of many mid-size companies. That financial strength is what made the Exact Sciences acquisition possible without a crisis.
Sources
- Abbott 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- Abbott 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- Abbott Q2 2026 earnings press release (PR Newswire)
- Abbott completes Exact Sciences acquisition (Abbott newsroom, March 23, 2026)
- Exact Sciences acquisition closing announcement (PR Newswire)
- Wolfe Research upgrade to Outperform, August 13, 2026 (MarketBeat)
- Abbott OTC glucose monitor FDA approvals, June 2024 (Forbes)
